Palak J Trivedi

Aug 15, 2024 | hcplive.com | Nancy Reau |Palak J Trivedi |Gideon Hirschfield |MB BChir

In recognition of the US Food and Drug Administration accelerated approval of Gilead's seladelpar (Livdelzi) and other recent evolutions in primary biliary cholangitis (PBC), the latest HCPLive Special Report spotlights a conversation between a trio of subject matter experts on the latest advancements in PBC and their implications for disease management.